Chlorthalidone
Quick Facts
Indications
| Indication | Approved Population / Product | Therapy Type | Status |
|---|---|---|---|
| Hypertension — to lower blood pressure (reduces fatal and non-fatal cardiovascular events, primarily stroke and MI) | Adults — all formulations (HemiClor, Thalitone, generic) | Monotherapy or in combination | FDA Approved |
| Edema — adjunctive therapy in heart failure, hepatic cirrhosis, and renal disease (including the nephrotic syndrome) per current Thalitone label; older generic chlorthalidone labels also include corticosteroid- and estrogen-induced edema | Adults — Thalitone (15/25 mg) and generic chlorthalidone tablets (HemiClor 12.5 mg is approved for hypertension only) | Adjunctive — combined with disease-specific therapy | FDA Approved |
Chlorthalidone — first FDA-approved in 1960 — is a long-acting thiazide-like diuretic structurally distinct from the benzothiadiazine thiazides. It carries the strongest cardiovascular outcome evidence of any thiazide-class agent: it was the active comparator in the SHEP, MRFIT, and ALLHAT trials, and is recommended over hydrochlorothiazide as the preferred thiazide-class diuretic in the 2017 ACC/AHA hypertension guideline. The FDA-approved indications differ slightly across products: HemiClor (12.5 mg) is approved only for hypertension in adults, while Thalitone (15 mg, 25 mg) and generic tablets (25 mg, 50 mg, 100 mg) carry both the hypertension and edema indications.
The 2022 Diuretic Comparison Project (DCP) — the first head-to-head pragmatic RCT against hydrochlorothiazide — showed no significant difference in major cardiovascular outcomes between chlorthalidone (12.5–25 mg) and HCTZ (25–50 mg) over 2.4 years in older adults overall, while hypokalemia was modestly more common on chlorthalidone. A pre-specified secondary analysis (Ishani 2024) did, however, find a significant interaction by cardiovascular history: in patients with prior MI or stroke, chlorthalidone was associated with lower MACE and noncancer death than HCTZ — though this finding requires confirmation in a primary trial.
Calcium nephrolithiasis prevention — chlorthalidone reduces urinary calcium excretion and lowers stone recurrence in idiopathic hypercalciuria. Recommended in AUA medical management of stones guideline. Typical dose 25 mg once daily. Evidence: high (multiple RCTs).
Resistant hypertension — chlorthalidone’s prolonged 24-hour BP coverage makes it a useful add-on. The CLICK trial (2021) supported chlorthalidone for resistant hypertension in advanced CKD, an area where thiazides were historically thought ineffective. Evidence: moderate.
Heart failure-associated edema — although not in the HemiClor label, the Thalitone label and generic chlorthalidone are FDA-approved for HF-associated edema; ACC/AHA HF guidelines support sequential nephron blockade with thiazide-like agents in resistant edema. Evidence: moderate.
Nephrogenic diabetes insipidus — paradoxical antidiuretic effect via volume contraction. Less commonly used than HCTZ for this indication. Evidence: low (small series).
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — adult (HemiClor 12.5 mg, 2025 PI) | 12.5 mg or 25 mg once daily | 25–50 mg/day | 100 mg once daily | Take with food. Double the dose every 2–4 weeks as needed; doses >100 mg do not increase efficacy Most cardiovascular outcome trials used 12.5–25 mg |
| Hypertension — adult (Thalitone 15 mg / 25 mg) | 15 mg once daily with food | 15–25 mg/day | 25 mg once daily | Thalitone is NOT interchangeable with other chlorthalidone formulations on a 1:1 mg basis (PVP-enhanced bioavailability) Doses >25 mg of Thalitone not expected to add benefit per label |
| Hypertension — adult (generic 25/50/100 mg tablets) | 25 mg once daily | 25–50 mg/day | 100 mg/day (rarely needed) | Take in the morning to limit nocturia. Doses >25 mg add little BP benefit but increase metabolic toxicity |
| Edema — adult (Thalitone, generic; not HemiClor) | 50–100 mg once daily, or 100 mg on alternate days | 50–100 mg/day or alternate-day | 200 mg/day | Decrease or increase based on response. Consider intermittent dosing to limit electrolyte loss |
| Heart failure-associated edema (per ACCF/AHA HF guideline) | 12.5–25 mg once daily | 25–50 mg/day | 100 mg/day | Often added to a loop diuretic for sequential nephron blockade in resistant edema |
| Calcium nephrolithiasis prevention (off-label, AUA guideline) | 25 mg once daily | 25 mg once daily | 50 mg/day | Combine with adequate fluid intake (>2 L/day); confirm hypercalciuria before initiating |
Renal Considerations
| Renal Function | Approach |
|---|---|
| eGFR ≥45 mL/min/1.73 m² | Standard dosing |
| eGFR 30–44 mL/min/1.73 m² | Reduced antihypertensive and diuretic effect; loop diuretic generally preferred for edema. Some efficacy retained for blood-pressure control. Monitor kidney function more frequently per FDA label — diuretics can precipitate AKI in CKD or volume-depleted patients. |
| eGFR <30 mL/min/1.73 m² | Largely ineffective as monotherapy — switch to a loop diuretic. The CLICK trial (Agarwal 2021, NEJM) showed chlorthalidone reduced BP in patients with advanced CKD on a loop diuretic, supporting use as add-on therapy in resistant hypertension despite low eGFR. |
| Anuria | Contraindicated per FDA labeling |
The FDA HemiClor 2025 label does not specify a numerical eGFR cutoff but warns that AKI risk is elevated in CKD, heart failure, and volume-depleted patients; cutoffs above are clinical-practice guidance.
Hepatic Adjustment
The FDA label does not provide a numerical dose adjustment for hepatic impairment but instructs clinicians to monitor fluid and electrolyte balance because minor changes in serum sodium or potassium can precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease. Initiate at the lowest effective dose and avoid abrupt fluid or electrolyte shifts in cirrhosis.
Geriatric, Pregnancy, Lactation & Pediatric
Per the FDA label, dose selection in older adults should begin at the low end of the dosing range, given the higher likelihood of decreased renal, hepatic, or cardiac function. Older adults are at higher risk for thiazide-induced hyponatremia, orthostatic hypotension, and falls. Pregnancy: chlorthalidone should not be used as first-line therapy for hypertension in pregnancy; advise pregnant women of potential fetal risk (jaundice, thrombocytopenia, hypoglycemia, electrolyte abnormalities). Lactation: chlorthalidone is present in human milk; the FDA HemiClor 2025 label specifically advises against breastfeeding during treatment, owing to the long half-life and potential for accumulation in the infant. Pediatric: safety and effectiveness have not been established (in contrast to hydrochlorothiazide, which is FDA-approved for pediatric use in the Inzirqo formulation).
For two decades, observational data and indirect comparisons (most prominently the Roush 2012 network meta-analysis) suggested chlorthalidone was superior to HCTZ for cardiovascular outcomes. The 2022 Diuretic Comparison Project — a pragmatic RCT in 13,523 older veterans — found no significant difference in the composite cardiovascular outcome between chlorthalidone (12.5–25 mg) and HCTZ (25–50 mg) at 2.4 years (HR 1.04, 95% CI 0.94–1.16, p=0.45). Hypokalemia was somewhat more common on chlorthalidone (6.0% vs 4.4%, p<0.001). A pre-specified subgroup analysis (Ishani 2024) detected a significant treatment-by-history interaction: in patients with prior MI or stroke, chlorthalidone was associated with lower MACE and noncancer death — though the overall trial was neutral and this hypothesis-generating finding has not been confirmed prospectively. The trial used lower doses than older outcome trials (which generally used ≥25 mg chlorthalidone or ≥50 mg HCTZ). Practical implication: chlorthalidone retains a guideline-level preference and stronger trial heritage, but is not clearly superior to HCTZ at modern low doses in average hypertensive patients. Either is reasonable; do not switch solely for presumed CV benefit.
Pharmacology
Mechanism of Action
Chlorthalidone is a long-acting oral diuretic. It produces diuresis by increasing urinary excretion of sodium and chloride at the cortical diluting segment of the ascending limb of the loop of Henle (per FDA label) — the same site as classical thiazide diuretics. At the molecular level, chlorthalidone inhibits the thiazide-sensitive sodium-chloride cotransporter (NCC; encoded by SLC12A3) in the distal convoluted tubule. The resulting decreases in extracellular fluid volume, plasma volume, cardiac output, and total exchangeable sodium underlie the antihypertensive effect — although, as the FDA label explicitly notes, “the mechanism of action of chlorthalidone and related drugs is not wholly clear.” Chlorthalidone also binds erythrocyte carbonic anhydrase, which contributes to its high red-blood-cell partitioning and prolonged terminal half-life.
Like other thiazides, chlorthalidone decreases urinary calcium excretion (a useful effect in calcium nephrolithiasis and a hypercalcemia caution per FDA label), increases urinary potassium and magnesium loss, and reduces uric acid clearance — driving its characteristic metabolic adverse-effect profile.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Absolute oral bioavailability ~64% (Fleuren 1979); the Thalitone formulation has 104–116% relative bioavailability vs oral solution due to PVP enhancement; diuretic onset ~2.6 h, duration 48–72 h | Take with food per FDA label. Thalitone cannot be substituted with other formulations on a 1:1 mg basis |
| Distribution | Plasma protein binding ~75% (58% to albumin per HemiClor PI); strong erythrocyte partitioning via carbonic anhydrase binding (blood:plasma ratio ~30); crosses the placenta and into breast milk | Pregnancy and lactation considerations are stronger than for HCTZ owing to the long half-life and accumulation potential |
| Metabolism | Limited information; data on percentage of dose as unchanged drug versus metabolites are not available per FDA label | No established CYP-based interactions |
| Elimination | Mean plasma t½ ~40 h after a 50–200 mg dose; ~53 h at 50 mg and ~60 h at 100 mg; eliminated primarily as unchanged drug in urine; non-renal routes not fully clarified per FDA label | Once-daily dosing produces 24-hour BP coverage. Long half-life requires several days to reach steady state and to wash out after discontinuation; missed doses do not lose effect quickly (a practical advantage over HCTZ) |
Side Effects
The FDA prescribing information for chlorthalidone (HemiClor 2025; Thalitone 2019; generic) lists adverse reactions by organ system but explicitly states that “there is not enough systematic collection of data to support an estimate of their frequency” — so no quantitative percentages are FDA-labeled. Frequencies in the tables below are taken from large pooled trial datasets, the SHEP, ALLHAT, and DCP 2022 trials, and pharmacoepidemiology analyses cited in the references — not from the FDA label itself. As with all thiazide-class agents, most adverse effects are dose-related, supporting the modern preference for 12.5–25 mg/day dosing.
| Adverse Effect | Approximate Incidence | Clinical Note |
|---|---|---|
| Asymptomatic hyperuricemia | ~25–40% (literature) | Increase is dose-related (FDA label). A smaller subset develops clinical gout. Comparable to HCTZ at equivalent doses |
| Hypokalemia (K⁺ <3.5 mEq/L) at older 50 mg doses | ~10–25% (literature, older trials) | Dose-related (FDA label). ALLHAT showed hypokalemia in ~12.7% at chlorthalidone 12.5–25 mg over 4 years. Lower at modern dosing |
| Adverse Effect | Approximate Incidence | Clinical Note |
|---|---|---|
| Hypokalemia at modern doses (12.5–25 mg) | 6.0% (DCP 2022) | Modestly higher than HCTZ at usual doses (4.4% in DCP, p<0.001). ACEi/ARB co-therapy attenuates the rise |
| Hyponatremia (Na⁺ <135 mEq/L) | ~5–15% (literature) | Markedly higher in older women and at low body weight. Severe hyponatremia (<125) is uncommon but can be life-threatening; long half-life means prolonged vulnerability |
| Hypomagnesemia | Common (lab finding) | FDA label notes that hypomagnesemia can produce hypokalemia refractory to potassium repletion alone — check Mg in resistant cases |
| Hypercalcemia (mild) | Listed in FDA label | Persistent or pronounced hypercalcemia should prompt evaluation for primary hyperparathyroidism, which thiazides can unmask. Discontinue thiazides before testing parathyroid function |
| Hyperglycemia / impaired glucose tolerance | ~3–5% (literature) | FDA label warns chlorthalidone may affect diabetes control and require antidiabetic dose adjustment. Risk concentrated in prediabetes/metabolic syndrome and correlates with degree of hypokalemia |
| Gout flare (in predisposed patients) | ~2–5% (literature) | Higher risk in men, prior gout history, and CKD. Reduced urate excretion is the mechanism |
| Hypotension / orthostatic hypotension | Listed in FDA label | FDA label specifically lists orthostatic hypotension as a cardiovascular adverse reaction. Volume depletion is the main driver |
| Erectile dysfunction (impotence) | Listed in FDA label | Reported in long-term thiazide trials. Often improves with dose reduction or class switch |
| Headache, dizziness, paresthesias, muscle spasm, weakness, restlessness | Listed in FDA label | FDA label lists these without specific frequency. Usually mild and transient |
| Hyperlipidemia (modest rise in cholesterol, triglycerides) | Listed in FDA label | Modest, dose-dependent rises; not typically a reason to discontinue therapy |
| Photosensitivity, rash, urticaria, purpura | Listed in FDA label | Counsel sun protection (broad-spectrum sunscreen, protective clothing); rare progression to severe cutaneous reactions warrants discontinuation |
| GI symptoms (anorexia, nausea, vomiting, cramping, diarrhea, constipation, gastric irritation) | Listed in FDA label | Persistent symptoms can compound volume depletion and electrolyte loss |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe symptomatic hyponatremia (Na⁺ <125 mEq/L) | Uncommon (~0.5–1% in older cohorts) | Days to weeks; spike in older women | Discontinue; correct sodium cautiously (≤8–10 mEq/L per 24 h) to avoid osmotic demyelination; do not rechallenge. Long half-life means several days for the drug effect to dissipate |
| Symptomatic hypokalemia (with ECG changes or muscle weakness) | Uncommon | Days to weeks | Per FDA label: monitor and correct K⁺ and Mg; consider class switch or addition of K⁺-sparing partner. Reduce dose first if symptomatic |
| Acute kidney injury (volume depletion, hypovolemia) | Uncommon | Days to weeks; precipitated by intercurrent illness, NSAIDs, ACEi/ARB | Hold drug per FDA label (Warning 5.1); address volume status, NSAIDs, and contrast exposure; consider withholding or discontinuing therapy if creatinine rise persists |
| Severe hypersensitivity reactions (anaphylaxis, vasculitis/necrotizing angiitis, cutaneous vasculitis) | Very rare (FDA label) | First dose to weeks | Permanent discontinuation; treat per anaphylaxis or organ-specific protocol |
| Lyell’s syndrome (toxic epidermal necrolysis) | Very rare (FDA label) | Days to weeks | Permanent discontinuation; urgent dermatology / burn-unit referral; supportive care |
| Pancreatitis | Very rare (FDA label) | Variable; weeks to years | Discontinue; standard pancreatitis care; do not rechallenge |
| Blood dyscrasias (aplastic anemia, agranulocytosis, thrombocytopenia, leukopenia) | Very rare (FDA label) | Variable | Discontinue; hematology consultation; supportive care |
| Hepatic encephalopathy / hepatic coma (in cirrhosis) | Rare overall; meaningful in advanced cirrhosis | Days; precipitated by minor electrolyte shifts and volume contraction | FDA label warns to monitor fluid/electrolyte balance; hold drug if encephalopathy develops |
| Possible activation of systemic lupus erythematosus | Reported with thiazides, structurally related; not specifically reported with chlorthalidone (per FDA HemiClor label) | Variable | Discontinue if lupus features develop or worsen; rheumatology referral |
Note on non-melanoma skin cancer: the 2020 FDA labeling change adding NMSC risk to hydrochlorothiazide has not been extended to chlorthalidone in current FDA labels. Some pharmacoepidemiology studies suggest a similar class-effect concern, but FDA labeling for chlorthalidone has not been updated; counsel sun protection on prudent grounds.
| Reason for Discontinuation | Approximate Frequency | Context |
|---|---|---|
| Persistent hypokalemia / muscle cramps | Common | Often manageable by adding ACEi/ARB or potassium supplementation rather than stopping |
| Hyponatremia | Common in elderly | One of the most frequent causes of hospital-acquired drug discontinuation in older adults; long chlorthalidone half-life prolongs vulnerability |
| Gout flare | Uncommon | Switching to losartan, ACEi, or CCB is reasonable |
| Erectile dysfunction | Uncommon | Often cited as a quality-of-life reason; class switch usually resolves |
Hypokalemia and hyponatremia together account for the majority of clinically meaningful adverse events. Mitigation is structured: confirm a baseline electrolyte panel before starting; recheck within 2–4 weeks, then at 3–6 months and after any dose increase or addition of an interacting drug. The FDA label explicitly requires correction of electrolytes before initiation. Use the lowest effective dose (12.5–25 mg) for hypertension. Pair routinely with an ACEi, ARB, or potassium-sparing diuretic in patients prone to hypokalemia. Counsel patients to report dizziness, lightheadedness, muscle cramps, or confusion early. The 40–60 hour half-life means that adverse effects may accumulate over the first 1–2 weeks and persist after discontinuation — be patient at initiation and after dose changes.
Drug Interactions
Chlorthalidone is not metabolised by CYP enzymes, so the most clinically meaningful interactions are pharmacodynamic — driven by additive electrolyte effects, additive blood-pressure effects, or interference with renal handling of co-administered drugs. The current FDA HemiClor 2025 label specifically lists four interactions: insulin/oral hypoglycemic agents, tubocurarine, norepinephrine, and lithium. Additional interactions below are well-established class effects from clinical-pharmacology references and the older Thalitone label.
Monitoring
-
Serum Electrolytes (K⁺, Na⁺, Cl⁻, HCO₃⁻, Mg²⁺, Ca²⁺)
Baseline → 2–4 weeks → 3–6 months → annually
Routine FDA label requires measurement and correction of electrolytes prior to use and periodic monitoring thereafter. Hypokalemia and hyponatremia drive most clinically meaningful events. Recheck within 1–2 weeks of dose change, intercurrent illness, or addition of corticosteroid, NSAID, or laxative. -
Serum Creatinine / eGFR
Baseline → with each electrolyte panel
Routine FDA label requires periodic kidney-function monitoring. A clinically significant decline should prompt withholding or discontinuation. Older adults are at heightened risk. -
Blood Pressure
Baseline → 2–4 weeks → quarterly until stable, then annually
Routine Allow 2–4 weeks for full BP response before titrating. Long half-life means trough effects are reliable; home BP monitoring catches both inadequate response and over-treatment. -
Uric Acid
Baseline → annually; or sooner if gout history
Routine (FDA label calls for periodic measurement) Asymptomatic hyperuricemia is common; persistent elevation in patients with prior gout warrants either dose reduction or class switch (losartan reduces urate). -
Glucose / HbA1c
Baseline → 3 months → annually
Routine (FDA label calls for periodic blood-sugar monitoring) Higher surveillance in prediabetes or metabolic syndrome. Antidiabetic drug doses may require adjustment per FDA label. -
Lipid Panel
Baseline → annually
Routine (FDA label calls for periodic lipid monitoring) Modest rises in cholesterol and triglycerides may occur; usually managed with standard cardiovascular risk-factor control rather than chlorthalidone discontinuation. -
Skin Examination
Annually; sooner if new lesion or fair skin
Prudent (not FDA-required for chlorthalidone) Unlike HCTZ, chlorthalidone does not carry an FDA labeling change for non-melanoma skin cancer; however, photosensitivity is a class effect, and prudent sun protection is reasonable. Watch for new growths in patients with prior NMSC or fair skin. -
Lithium level
During concomitant use; recheck after any chlorthalidone dose change
Trigger-based (FDA-required) Lithium dose typically requires reduction. Owing to chlorthalidone’s long half-life, recheck levels for several weeks after any dose change.
For uncomplicated hypertension on chlorthalidone 12.5–25 mg: baseline electrolytes, creatinine, glucose, uric acid, and lipids; recheck electrolytes and creatinine at 2–4 weeks, then at 3–6 months, and annually thereafter. Add an interval check after any dose change, hospitalisation, or addition of an interacting drug. The long (40–60 h) half-life means changes accumulate and resolve more slowly than with HCTZ — be patient at initiation and after dose changes.
Contraindications & Cautions
Absolute Contraindications (FDA Label)
- Anuria.
- Hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. Cross-reactivity between antibiotic sulfonamides and non-antibiotic sulfonamides such as chlorthalidone is uncertain; clinical-pharmacology references note that the cross-reactivity may be low, but the FDA label retains the broad contraindication.
Relative Contraindications (Specialist Input or Class Change Recommended)
- Severe renal impairment (eGFR <30 mL/min/1.73 m²) — chlorthalidone loses efficacy as a monotherapy diuretic; switch to a loop diuretic. May still be added to a loop diuretic in resistant edema (specialist setting). The CLICK trial supports use as add-on for resistant hypertension in advanced CKD. FDA label warns of AKI risk in CKD without specifying a numerical cutoff.
- Advanced hepatic impairment / decompensated cirrhosis — minor fluid and electrolyte shifts can precipitate hepatic coma per FDA label; monitor mental status closely or avoid.
- Severe hyponatremia or refractory hypokalemia at baseline — correct first; investigate cause. The FDA label requires correction of electrolytes before initiation.
- Active gout — consider losartan, ACEi, or CCB as alternative antihypertensive.
- Pregnancy — not first-line per FDA label; advise pregnant women of potential fetal risk (jaundice, thrombocytopenia, hypoglycemia, electrolyte abnormalities).
- Lactation — FDA label specifically advises against breastfeeding during treatment (in contrast to HCTZ, where breastfeeding can usually continue at low doses).
- Pediatric patients — safety and effectiveness not established per FDA label.
Use with Caution
- Diabetes mellitus — may affect glycemic control; antidiabetic drug doses may need adjustment per FDA label.
- Older adults, particularly older women — heightened risk of hyponatremia and falls; start at the low end of the dose range (12.5 mg).
- Patients on QT-prolonging drugs — maintain potassium and magnesium tightly.
- Volume-depleted patients — heightens AKI and orthostatic risk; rehydrate before initiation.
- Hypercalcemic states — chlorthalidone can elevate serum calcium; monitor closely. Discontinue thiazides before testing parathyroid function.
- Patients with allergic or asthmatic disposition — hypersensitivity reactions may be more likely (per Thalitone label).
Chlorthalidone does not carry a boxed warning. The principal labeled warnings are: (1) Acute kidney injury — diuretics can cause hypovolemia precipitating AKI; patients with CKD, heart failure, or volume depletion are at particular risk. (2) Electrolyte abnormalities — dose-dependent hypokalemia, hyponatremia, hypomagnesemia, and hypochloremic alkalosis; correct electrolytes before initiation and monitor periodically. (3) Metabolic disturbances — hyperglycemia, hyperlipidemia, hyperuricemia, and hypercalcemia. (4) Possible exacerbation or activation of systemic lupus erythematosus — reported with structurally related thiazide diuretics; not specifically reported with chlorthalidone per FDA label.
Note: the August 2020 FDA labeling change adding non-melanoma skin cancer risk to hydrochlorothiazide has not been extended to chlorthalidone in current labels. Pharmacoepidemiology studies suggest a similar class-effect concern; counsel sun protection on prudent grounds.
Patient Counselling
Purpose of Therapy
Chlorthalidone is a “water tablet” used to lower blood pressure or remove excess fluid from the body. In high blood pressure, it works gradually over 2–4 weeks to reduce the workload on the heart and arteries — patients should not expect to feel the medication doing anything. Lowering blood pressure protects against stroke, heart attack, kidney damage, and heart failure over the long term. Chlorthalidone has been used safely for over 60 years and was the diuretic in landmark trials that established the value of treating high blood pressure in older adults. Its long duration of action means a single daily dose covers 24 hours.
How to Take
Take the tablet once daily with food, ideally in the morning, so the increased urination occurs during the day rather than at night. If a dose is missed, take it as soon as remembered the same day; if it is nearly time for the next dose, skip the missed dose entirely — never double up. Because chlorthalidone has a long action, missing one dose has less impact than missing some other blood-pressure medications. Do not stop the medication without speaking with the prescribing clinician, even if blood pressure feels normal. Blood tests for potassium, sodium, and kidney function are part of the prescription; missing them is not optional.
Sources
- U.S. Food and Drug Administration. HEMICLOR™ (chlorthalidone) tablets, 12.5 mg — Highlights of Prescribing Information. PRM Pharma LLC. Revised March 2025; Reference ID: 5550640. accessdata.fda.gov/drugsatfda_docs/label/2025/218647s000lbl.pdf Most recently approved chlorthalidone label (12.5 mg, hypertension-only indication); primary source for current dosing, contraindications, and warnings.
- U.S. Food and Drug Administration. THALITONE® (chlorthalidone) tablets USP 15 mg and 25 mg — Prescribing Information. accessdata.fda.gov/drugsatfda_docs/label/2019/019574s017lbl.pdf Reference label for the PVP-enhanced formulation; the only currently approved low-dose chlorthalidone product carrying both HTN and edema indications. Not interchangeable with generic chlorthalidone on a 1:1 mg basis.
- SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–3264. doi.org/10.1001/jama.1991.03460240051027 Foundational chlorthalidone outcome trial showing 36% reduction in total stroke (5-year incidence 5.2 vs 8.2 per 100) in older adults with isolated systolic hypertension.
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA. 2002;288(23):2981–2997. doi.org/10.1001/jama.288.23.2981 Largest randomised hypertension trial; chlorthalidone non-inferior on the primary outcome (fatal CHD/nonfatal MI) and superior to lisinopril and amlodipine for heart failure prevention.
- Ishani A, Cushman WC, Leatherman SM, et al; Diuretic Comparison Project Writing Group. Chlorthalidone vs. hydrochlorothiazide for hypertension–cardiovascular events. N Engl J Med. 2022;387(26):2401–2410. doi.org/10.1056/NEJMoa2212270 First head-to-head pragmatic RCT in 13,523 older veterans; no significant difference in CV outcomes between chlorthalidone (12.5–25 mg) and HCTZ (25–50 mg) over 2.4 years (HR 1.04, 95% CI 0.94–1.16).
- Ishani A, Hau C, Cushman WC, et al. Chlorthalidone vs hydrochlorothiazide for hypertension treatment after myocardial infarction or stroke: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(5):e2411081. doi.org/10.1001/jamanetworkopen.2024.11081 DCP secondary analysis: significant treatment-by-history interaction — chlorthalidone associated with lower MACE and noncancer death than HCTZ in patients with prior MI or stroke. Hypothesis-generating.
- Sica D, Bakris GL, White WB, et al. Antihypertensive efficacy of low-dose chlorthalidone (12.5 mg) compared with hydrochlorothiazide (25 mg) in adults with hypertension. J Clin Hypertens. 2012;14(5):284–292. doi.org/10.1111/j.1751-7176.2012.00626.x Cited in the FDA HemiClor 2025 label as the principal efficacy support for the 12.5 mg starting dose.
- Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease (CLICK). N Engl J Med. 2021;385(27):2507–2519. doi.org/10.1056/NEJMoa2110730 First trial demonstrating chlorthalidone’s BP-lowering efficacy in stage 4 CKD; supports add-on use to loop diuretics in resistant hypertension despite low eGFR.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13–e115. doi.org/10.1161/HYP.0000000000000065 Recommends chlorthalidone as the preferred thiazide-class diuretic for hypertension based on cardiovascular outcome evidence and prolonged half-life.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi.org/10.1097/HJH.0000000000003480 European hypertension guideline endorsing thiazide-like diuretics (chlorthalidone, indapamide) among preferred initial therapies.
- Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316–324. doi.org/10.1016/j.juro.2014.05.006 AUA guideline supporting thiazide use (including chlorthalidone 25 mg) for prevention of recurrent calcium kidney stones.
- Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110–1117. doi.org/10.1161/HYPERTENSIONAHA.112.191106 Indirect comparison suggesting greater CV event reduction with chlorthalidone than HCTZ; subsequently challenged by the DCP 2022 head-to-head trial in average hypertensive patients.
- Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352–358. doi.org/10.1161/01.HYP.0000203309.07140.d3 Demonstrated greater 24-hour BP coverage with chlorthalidone, supporting its longer half-life advantage.
- Fleuren HLJ, Thien TA, Verwey-van Wissen CPW, van Rossum JM. Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration. Eur J Clin Pharmacol. 1979;15(1):35–50. doi.org/10.1007/BF00563556 Source for the ~64% absolute oral bioavailability figure for generic chlorthalidone.
- Ernst ME, Fravel MA. Thiazide and the thiazide-like diuretics: review of hydrochlorothiazide, chlorthalidone, and indapamide. Am J Hypertens. 2022;35(7):573–586. doi.org/10.1093/ajh/hpac048 Comprehensive comparative review covering pharmacology, dosing, and outcome data for the three principal thiazide-class agents.
- Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158(6):447–455. doi.org/10.7326/0003-4819-158-6-201303190-00004 Observational study suggesting greater hypokalemia and similar CV outcomes for chlorthalidone vs HCTZ; foreshadowed DCP findings.
- Edwards C, Hundemer GL, Petrcich W, et al. Comparison of clinical outcomes and safety associated with chlorthalidone vs hydrochlorothiazide in older adults with varying levels of kidney function. JAMA Netw Open. 2021;4(9):e2123365. doi.org/10.1001/jamanetworkopen.2021.23365 Population-based analysis showing higher rates of hypokalemia and hyponatremia with chlorthalidone, particularly in CKD.
- Ishani A, Hau C, Raju S, et al. Chlorthalidone vs hydrochlorothiazide and kidney outcomes in patients with hypertension: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(12):e2449576. doi.org/10.1001/jamanetworkopen.2024.49576 DCP kidney-outcomes secondary analysis examining differences in renal function decline between chlorthalidone and HCTZ.